-+ 0.00%
-+ 0.00%
-+ 0.00%

Watson Biotech announced that its subsidiary Yuxi Zerun Biotechnology Co., Ltd. participated in the bidding process for the “2025 National Immunization Plan Vaccine Centralized Procurement Project - Bivalent Human Papillomavirus Vaccine Procurement Project”, and the Yuxi Zerun Bivalent Human Papillomavirus Vaccine Bivalent Human Papillomavirus Vaccine was shortlisted. The shortlisted unit price is RMB 27.5. The Yuxi Zerun bivalent HPV vaccine is mainly used to prevent related diseases caused by high-risk HPV types 16 and 18, such as cervical cancer, grade 2 and grade 3 cervical intraepithelial neoplasia, and cervical adenocarcinoma in situ.

Zhitongcaijing·12/23/2025 10:41:14
Listen to the news
Watson Biotech announced that its subsidiary Yuxi Zerun Biotechnology Co., Ltd. participated in the bidding process for the “2025 National Immunization Plan Vaccine Centralized Procurement Project - Bivalent Human Papillomavirus Vaccine Procurement Project”, and the Yuxi Zerun Bivalent Human Papillomavirus Vaccine Bivalent Human Papillomavirus Vaccine was shortlisted. The shortlisted unit price is RMB 27.5. The Yuxi Zerun bivalent HPV vaccine is mainly used to prevent related diseases caused by high-risk HPV types 16 and 18, such as cervical cancer, grade 2 and grade 3 cervical intraepithelial neoplasia, and cervical adenocarcinoma in situ.